Free Trial

Inhibitor Therapeutics Q4 2023 Earnings Report

Inhibitor Therapeutics logo
$0.06 -0.01 (-17.50%)
(As of 12/20/2024 05:55 PM ET)

Inhibitor Therapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Inhibitor Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inhibitor Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibitor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibitor Therapeutics and other key companies, straight to your email.

About Inhibitor Therapeutics

Inhibitor Therapeutics (OTCMKTS:INTI), a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

View Inhibitor Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings